Naveen Pemmaraju, MD

Articles

JAK Inhibitors in Myelofibrosis

April 12th 2023

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.

Transplant Therapy in Myelofibrosis

April 5th 2023

Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.

Myelofibrosis: Diagnosis and Prognostic Risk Assessment

April 5th 2023

Comprehensive discussion highlighting diagnostic and molecular testing involved in the diagnosis of myelofibrosis, challenges related to early diagnosis, and consideration factors for assessing prognostic risk.

Myelofibrosis: Classification, Risk Factors, and Biomarkers

March 29th 2023

Shared insight on classification, risk factors, and important biomarkers and pathways in myelofibrosis.

Polycythemia Vera: Prognosis and Risk for Progression to Myelofibrosis

March 29th 2023

Panel experts share insight regarding prognosis for patients with polycythemia vera and the associated risk for progression to myelofibrosis.

Systemic Treatment Options for Polycythemia Vera

March 22nd 2023

A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.

Overview of MPNs

March 22nd 2023

A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.

Expanding Novel Treatment Options for Patients With T-Cell ALL

February 2nd 2023

A brief review of T-Cell acute lymphoblastic leukemia and emerging novel therapies that may improve upon its existent treatment armamentarium.

Unmet Needs and Future Directions in the Management of Myelofibrosis

February 2nd 2023

Naveen Pemmaraju, MD, highlights unmet needs in the setting of myelofibrosis management and looks toward future evolutions in the treatment paradigm.

Interpreting Data From the REFINE Study: Ruxolitinib + Navitoclax in Myelofibrosis

February 2nd 2023

Expert perspectives on specific subsets of the REFINE study, which combined ruxolitinib with navitoclax in patients diagnosed with myelofibrosis.

Disease Modification in Myelofibrosis: The Current Treatment Paradigm

February 2nd 2023

Shifting his focus to treatment strategies in myelofibrosis, Naveen Pemmaraju, MD, reviews the current drug armamentarium and explains how it ties into disease modification.

Overview on Myelofibrosis: Diagnosis, Staging, and Molecular Testing

February 2nd 2023

Expert hematologist-oncologist Naveen Pemmaraju, MD, highlights current strategies in diagnosing and stratifying patients with myelofibrosis.

Myeloproliferative Neoplasm Management: Future Directions in Care

February 2nd 2023

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Sequencing and Managing Combination Therapy in Myeloproliferative Neoplasms

January 26th 2023

Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.

An Expanding Armamentarium in MPNs: Therapeutic Strategies Under Investigation

January 26th 2023

A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.

Myeloproliferative Neoplasms: Targeting CALR With Novel Therapy

January 19th 2023

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.

What is the Role of Transplant in Managing Patients With Myelofibrosis?

January 19th 2023

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Therapy in Myelofibrosis: Fedratinib and Ruxolitinib Strategies

January 12th 2023

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

Myelofibrosis: Nuancing the Potential of Disease Modification

January 12th 2023

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

Therapy in Myelofibrosis: Pacritinib

January 5th 2023

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.